We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Drug Discovery: Focus on Small Molecule Kinase Inhibitors

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Drug Discovery: Focus on Small Molecule Kinase Inhibitors "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Research and Markets has announced the addition of "Kinases: Advanced Strategies and Multiple Targets for Drug Discovery" to their offering.

Kinases: Advanced Strategies and Multiple Targets for Drug Discovery market analysis report reviews protein kinases and assesses their importance as drug targets.

Approaches to kinase drug discovery are evolving. Small molecule inhibitors now encompass rationally-designed single-target inhibitors and multi-target inhibitors developed with the aid of screening and profiling assays.

During the last five years, eight anticancer kinase inhibitors received FDA approval, including multi-kinase inhibitors, the first of which was approved by the FDA in December 2005.

The launched drugs are discussed in this report, as are similar agents that are following in their track.

At the same time, recent discoveries of activating and resistance kinase mutations have been driving the development of molecularly targeted anticancer therapies and Research and Markets review progress in this area.

An on-line survey conducted specially for this report shows that kinases (alongside GPCRs), are currently regarded as commercially the promising targets available to the drug industry.

The facts and analysis provided by this report help companies prepare themselves to exploit these targets.

Buy this report and receive:

- Results from a survey of 800 kinase drugs and their targets

- Current market size and forecasts to 2010 to assist the reader with formulating business plans in the kinase drug area

- Analysis on the leading indications for kinase drugs and highlights in areas of unmet needs to enable the reader to formulate a strategy for business development

- Profiles of kinase-related patenting at the US PTO to help the reader understand the area's IP landscape, identify trends, improve strategic approach and discover potential collaborative partners

- Analysis of kinase drug targets through a gene family-based approach to allow the reader to assess the drug development potential of kinases belonging to particular families

The report contains answers to questions in this area such as:

- Which kinase targets are being pursued by drug developers?

- Which kinase targets have attracted the greatest amount of interest from drug developers?

- What is the nature of commercial activity surrounding each major kinase target?

- Which are the most important therapeutic indications for kinase drugs?

- What are the areas of unmet need that new kinase drugs could address?

- Which companies are the most prolific developers of kinase drugs and what drugs are in their portfolios?

- Who are the most prolific assignees and which are the most frequently cited kinase patents?

Recent approvals of several first-in-class kinase inhibitors have resulted in increased recognition of kinases as an important class of drug targets.

The kinase market is still at an early stage, but many trends are already evident and these are analyzed in this report.

Already 145 kinase-related genes are being targeted in kinase drug development, which nonetheless leaves a large number (estimated 627) of potential targets unexplored.

This report guides readers in assessing or reassesing their strategies with respect to this target class.

In order to assess recent progress and prospects in the kinase field, several surveys were carried out exclusively for this report, involving searches of the Pharmaprojects database and the U.S. Patent and Trademark Office database, and questioning of respondents from the pharmaceutical industry.

The information from the various surveys was utilized in the analysis of individual kinase targets and families to which they belong.

During the last five years, eight anticancer kinase inhibitors received FDA approval, increasing recognition of kinases as an important class of drug targets.

In order to assess the scientific, clinical, and commercial progress and prospects in this field, the following surveys were carried out for this report: a search of Pharmaprojects, the leading database tracking pharmaceutical R&D worldwide; a survey of the last six years of kinase-related patenting at the US PTO; and an on-line survey of pharmaceutical industry and academic personnel.

Companty forecast that the kinase-targeted drug market will grow from $12.7 billion in 2005 to $58.6 billion in 2010. Cancer (mainly solid tumors) will remain the dominant application throughout the forecast period.

Reversible protein phosphorylation, catalyzed by kinases, is a ubiquitous mechanism for the control of signal transduction networks that regulate many vital biological processes.

Cancer and other proliferation-related disorders are associated with stimulation of intra-cellular signaling, and since kinases (most of the time) positively relay signaling events; their inhibition offers a way to block aberrant signal transduction cascades.

The focus throughout this report is on inhibitors of protein kinases, although, where appropriate, protein kinase stimulators are also discussed, as are modulators of lipid and sugar kinases.